Kapitalo Investimentos’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kapitalo Investimentos’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78,586	Closed	-$10.4M	–	171
2025 Q1	$10.4M	Buy	+78,586	New	+$9.79M	2.1%	15
2024 Q2	–	Sell	-3,549	Closed	-$246K	–	321
2024 Q1	$246K	Buy	3,549 +3,181	+864%	+$219K	0.05%	216
2023 Q4	$26.4K	Buy	+368	New	+$21.2K	0.01%	484
2023 Q3	–	Sell	-654	Closed	-$41.4K	–	706
2023 Q2	$41.4K	Buy	+654	New	+$40.8K	0.01%	413

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kapitalo Investimentos's ITCI Position: Q2 2025 in Review

Kapitalo Investimentos sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 78,586 shares — an estimated $10.4M sold.

Kapitalo Investimentos first reported a position in ITCI in Q2 2023 and held it in 4 quarters. The position peaked at $10.4M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Kapitalo Investimentos reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Kapitalo Investimentos sold 78,586 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $10.4M.
Kapitalo Investimentos first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 4 quarters.
Kapitalo Investimentos's Intra-Cellular Therapies Inc. position peaked at $10.4M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Kapitalo Investimentos's 13F filing for Q2 2025, filed 14 Jul 2025.